Home > > > > Report Detail

Cancer Vaccines Market, Pipeline Analysis Report 2020

Publisher Name :
Date: 29-Jun-2020
No. of pages: 115

"“Global Cancer Vaccines market size is expected to surpass US$ 8.5 Billion by 2025”

Report Scope:

• Detailed Insights of the Introduction to Cancer Vaccines and Mechanism of Cancer Vaccines

• The Market Size of the Global Cancer Vaccines Market with Five Years Forecast

• The Market Size of the 4 Leading Cancer Vaccines with Five Years Forecast

• Provides Comprehensive Insights on the Funding of the Cancer Vaccines Research

• Investigates the Key Growth Drivers and Restraints of the Global Cancer Vaccines Market

• Provides Key Trends with Respect to Collaboration Deals, Merger & Acquisitions, Partnership Deals, and Licensing Agreement

• Detailed Insights of the Regulatory Framework Including the Approval Process and an Overview of the Regulatory Authorities in the United States, EU, and Japan

• A Comprehensive List of the Key Players Along with the Analysis of their Current Vaccines Portfolios, Promising Vaccines in the Clinical Development, Sales Value Analysis, and Recent Development

• An Insightful Analysis of the Emerging Players Along with the Analysis of their Promising Vaccines in the Clinical Development, Phase, Platform Technology, and Recent Development

“Cancer Vaccines Market, Pipeline Analysis Report, 2020” provides a comprehensive analysis of the fast-evolving, high-growth global cancer vaccines market. The report offers the foremost up-to-date industry data on the specific market situation and future outlook for the global cancer vaccines market. The report provides historical market data for 2015 – 2019, and forecasts from 2020 till 2025.

The report contains a granular evaluation of the prevailing enterprise conditions, market demands, reveal facts in the marketplace, revenues, and offers forecasts through 2025. The report presents clear perception into current and future developments of the global cancer vaccines market.

The report explores detailed insights into the introduction to cancer vaccines and the mechanism of cancer vaccines. The report additionally provides a detailed evaluation of the leading 4 key marketed cancer vaccines market assessments globally, data from 2015 to 2019, and forecasts to 2025. The report reviews a clear insight into the funding of the cancer vaccines studies. The report additionally investigates special insights about the regulatory landscape which include the approval system and an overview of the regulatory authorities in the United States, EU, and Japan.

Key developments of collaboration, partnerships, merger & acquisition, and licensing settlement are analyzed with details. The report additionally examines the principle marketplace growth drivers and restraining forces and also offers an all-round future outlook.

The report concludes with the profiles of the key players in the global cancer vaccines market. The key players are evaluated on various parameters such as business overview, vaccines portfolio, vaccines revenue analysis, and recent development.

Other emerging players are making novel era-based vaccines that are in all possibility to have an effect on the market share during the forecast duration. The emerging players are evaluated on various parameters such as business overview, promising vaccines in the clinical development with the current stage of clinical evaluation, vaccines target, platform technology, and recent developments.

The following 4 leading vaccines of the global cancer vaccines market are detailed with market size and five-year forecast:

• Gardasil/Gardasil 9

• Cervarix

• Provenge

• Imlygic

The foremost companies dominating this market for its products, offerings, and non-stop product trends are:

• Amgen

• Merck & Co., Inc

• GlaxoSmithKline (GSK)

• Dendreon Pharmaceuticals (Sanpower Group)

• GeoVax,Inc

• Moderna, Inc

• Flow Pharma, Inc

• Polynoma LLC

• IO Biotech

• OncoPep, Inc

• Medigen, Inc

• ViciniVax

• ImmuneTune

• Treos Bio Limited

• EpiThany

• CureVac AG

• DCprime

• Vaximm AG

• AdaptVac

• MimiVax LLC

• Agenus, Inc

• AlphaVax, Inc

• Genexine

• GlobeImmune, Inc

• Ubivac, Inc

• Vaccinogen, Inc

• Genocea Biosciences, Inc

• Northwest Biotherapeutics, Inc

• OncBioMune Pharmaceuticals, Inc

• Inovio Pharmaceuticals, Inc

• Enochian Biosciences

• Eu Biologics Co., Ltd.

• EVOQ Therapeutics

• Heat Biologics, Inc

• Scancell Holdings PLC

• Anixa Biosciences, Inc

• PDC*line Pharma

• Elios Therapeutics, LLC

• OSE Immunotherapeutics

The Report Helps Solution the Following Questions:

• What is the current size of the overall global cancer vaccines market? How much will this market be worth from 2020 to 2025?

• What are the key marketed cancer vaccines? What are their revenue potentials to 2025?

• What are the main drivers and restraints in the global cancer vaccines market?

• What are the major deals happenings in the global cancer vaccines market?

• Who are the top market players and what are their happenings, vaccines revenue, current developments, and scenarios?

• What are some of the most prominent cancer vaccines currently in clinical development? What are their happenings, platform technology, and current developments?

Cancer Vaccines Market, Pipeline Analysis Report 2020

Table of Contents

1. Executive Summary

2. Introduction to Cancer Vaccines

3. Mechanism of Cancer Vaccines

4. Global Cancer Vaccines Market Size and Forecast (2015 – 2025)

5. Key Marketed Cancer Vaccines Market Value (2015 – 2025)
5.1 Gardasil/Gardasil 9
5.2 Cervarix
5.3 Provenge
5.4 Imlygic

6. Key Market Drivers and Inhibitors of the Cancer Vaccines Market
6.1 Key Market Drivers
6.2 Key Market Inhibitors

7. Funding in the Cancer Vaccines Research

8. Major Deals and Agreement Happenings in the Cancer Vaccines Market
8.1 Collaboration Deals
8.2 Licensing Agreement
8.3 Partnership Deals
8.4 Merger & Acquisitions

9. Regulatory Environment – Cancer Vaccines Approval Process
9.1 United States
9.2 Europe
9.3 Japan

10. Key Players Analysis
10.1 Merck & Co., Inc.
10.1.1 Business Overview
10.1.2 Vaccines Portfolio
10.1.3 Recent Development
10.2 GlaxoSmithKline (GSK)
10.2.1 Business Overview
10.2.2 Vaccines Portfolio
10.3 Dendreon Pharmaceuticals (Sanpower Group)
10.3.1 Business Overview
10.3.2 Vaccines Portfolio
10.3.3 Recent Development
10.4 Amgen
10.4.1 Business Overview
10.4.2 Vaccines Portfolio
10.4.3 Recent Development

11. Emerging Players Analysis
11.1 Genocea Biosciences,Inc
11.1.1 Business Overview
11.1.2 Promising Cancer Vaccines in the Clinical Development
11.1.3 Recent Development
11.2 GeoVax, Inc
11.2.1 Business Overview
11.2.2 Promising Cancer Vaccines in the Clinical Development
11.2.3 Recent Development
11.3 Moderna, Inc
11.3.1 Business Overview
11.3.2 Promising Cancer Vaccines in the Clinical Development
11.3.3 Recent Development
11.4 Northwest Biotherapeutics, Inc
11.4.1 Business Overview
11.4.2 Promising Vaccines in the Clinical Development
11.4.3 Recent Development
11.5 OncBioMune Pharmaceuticals, Inc
11.5.1 Business Overview
11.5.2 Promising Vaccines in the Clinical Development
11.5.3 Recent Development
11.6 Inovio Pharmaceuticals, Inc
11.6.1 Business Overview
11.6.2 Promising Cancer Vaccines in the Clinical Development
11.6.3 Recent Development
11.7 Enochian Biosciences
11.7.1 Business Overview
11.7.2 Promising Cancer Vaccines in the Clinical Development
11.8 Flow Pharma, Inc
11.8.1 Business Overview
11.8.2 Promising Cancer Vaccines in the Clinical Development
11.8.3 Recent Development
11.9 Polynoma LLC
11.9.1 Business Overview
11.9.2 Promising Cancer Vaccines in the Clinical Development
11.9.3 Recent Development
11.10 IO Biotech
11.10.1 Business Overview
11.10.2 Promising Cancer Vaccines in the Clinical Development
11.10.3 Recent Development
11.11 Eu Biologics Co., Ltd.
11.11.1 Business Overview
11.11.2 Promising Cancer Vaccines in the Clinical Development
11.12 OncoPep, Inc
11.12.1 Business Overview
11.12.2 Promising Cancer Vaccines in the Clinical Development
11.12.3 Recent Development
11.13 Medigen, Inc
11.13.1 Business Overview
11.13.2 Promising Cancer Vaccines in the Clinical Development
11.14 EVOQ Therapeutics
11.14.1 Business Overview
11.14.2 Promising Cancer Vaccines in the Clinical Development
11.15 Heat Biologics, Inc
11.15.1 Business Overview
11.15.2 Promising Cancer Vaccines in the Clinical Development
11.15.3 Recent Development
11.16 ViciniVax
11.16.1 Business Overview
11.16.2 Promising Cancer Vaccines in the Clinical Development
11.17 ImmuneTune
11.17.1 Business Overview
11.17.2 Promising Cancer Vaccines in the Clinical Development
11.18 Elios Therapeutics LLC
11.18.1 Business Overview
11.18.2 Promising Cancer Vaccines in the Clinical Development
11.18.3 Recent Development
11.19 Treos Bio Limited
11.19.1 Business Overview
11.19.2 Promising Cancer Vaccines in the Clinical Development
11.19.3 Recent Development
11.20 Scancell Holdings PLC
11.20.1 Business Overview
11.20.2 Promising Cancer Vaccines in the Clinical Development
11.20.3 Recent Development
11.21 EpiThany
11.21.1 Business Overview
11.21.2 Promising Cancer Vaccines in the Clinical Development
11.21.3 Recent Development
11.22 CureVac AG
11.22.1 Business Overview
11.22.2 Promising Cancer Vaccines in the Clinical Development
11.22.3 Recent Development
11.23 DCprime
11.23.1 Business Overview
11.23.2 Promising Cancer Vaccines in the Clinical Development
11.23.3 Recent Development
11.24 Vaximm AG
11.24.1 Business Overview
11.24.2 Promising Cancer Vaccines in the Clinical Development
11.24.3 Recent Development
11.25 Anixa Biosciences, Inc
11.25.1 Business Overview
11.25.2 Promising Cancer Vaccines in the Clinical Development
11.25.3 Recent Development
11.26 AdaptVac
11.26.1 Business Overview
11.26.2 Promising Cancer Vaccines in the Clinical Development
11.26.3 Recent Development
11.27 PDC*line Pharma
11.27.1 Business Overview
11.27.2 Promising Cancer Vaccines in the Clinical Development
11.27.3 Recent Development
11.28 MimiVax LLC
11.28.1 Business Overview
11.28.2 Promising Cancer Vaccines in the Clinical Development
11.28.3 Recent Development
11.29 Agenus, Inc
11.29.1 Business Overview
11.29.2 Promising Cancer Vaccines in the Clinical Development
11.30 AlphaVax, Inc
11.30.1 Business Overview
11.30.2 Promising Cancer Vaccines in the Clinical Development
11.31 Genexine
11.31.1 Business Overview
11.31.2 Promising Cancer Vaccines in the Clinical Development
11.31.3 Recent Development
11.32 GlobeImmune, Inc
11.32.1 Business Overview
11.32.2 Promising Cancer Vaccines in the Clinical Development
11.33 Ubivac, Inc
11.33.1 Business Overview
11.33.2 Promising Cancer Vaccines in the Clinical Development
11.34 Vaccinogen, Inc
11.34.1 Business Overview
11.34.2 Promising Cancer Vaccines in the Clinical Development
11.35 OSE Immunotherapeutics
11.35.1 Business Overview
11.35.2 Promising Cancer Vaccines in the Clinical Development
11.35.3 Recent Development

List of Figures:

Figure 4–1: Global Cancer Vaccines Market Size (Million US$), 2015 – 2019
Figure 4–2: Global Cancer Vaccines Market Forecast (Million US$), 2020 – 2025
Figure 5–1: Gardasil/Gardasil 9 Market Value Analysis (Million US$), 2015 – 2019
Figure 5–2: Gardasil/Gardasil 9 Market Value Forecast (Million US$), 2020 – 2025
Figure 5–3: Cervarix Market Value Analysis (Million US$), 2015 – 2019
Figure 5–4: Cervarix Market Value Forecast (Million US$), 2020 – 2025
Figure 5–5: Provenge Market Value Analysis (Million US$), 2015 – 2019
Figure 5–6: Provenge Market Value Forecast (Million US$), 2020 – 2025
Figure 5–7: Imlygic Market Value Analysis (Million US$), 2016 – 2019
Figure 5–8: Imlygic Market Value Forecast (Million US$), 2020 – 2025

List of Tables:

Table 8–1: Collaboration Deals in the Cancer Vaccines Market
Table 8–2: Licensing Agreement in the Cancer Vaccines Market
Table 8–3: Partnership Deals in the Cancer Vaccines Market
Table 8–4: Merger & Acquisitions in the Cancer Vaccines Market
Table 9–1: United States – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 9–2: European Union – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 9–3: Japan – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 11–1: Genocea Biosciences, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–2: GeoVax, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–3: Moderna, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–4: Northwest Biotherapeutics, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–5: OncBioMune Pharmaceuticals, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–6: Inovio Pharmaceuticals, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–7: Enochian Biosciences Promising Cancer Vaccines in the Clinical Development
Table 11–8: Flow Pharma, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–9: Polynoma LLC Promising Cancer Vaccines in the Clinical Development
Table 11–10: IO Biotech Promising Cancer Vaccines in the Clinical Development
Table 11–11: Eu Biologics Co., Ltd. Promising Cancer Vaccines in the Clinical Development
Table 11–12: OncoPep Promising Cancer Vaccines in the Clinical Development
Table 11–13: Medigen, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–14: EVOQ Therapeutics Promising Cancer Vaccines in the Clinical Development
Table 11–15: Heat Biologics, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–16: Vicinivax Promising Cancer Vaccines in the Clinical Development
Table 11–17: ImmuneTune Promising Cancer Vaccines in the Clinical Development
Table 11–18: Elios Therapeutics Promising Cancer Vaccines in the Clinical Development
Table 11–19: Treos Bio Limited Promising Cancer Vaccines in the Clinical Development
Table 11–20: Scancell Holdings PLC Promising Cancer Vaccines in the Clinical Development
Table 11–21: EpiThany Promising Cancer Vaccines in the Clinical Development
Table 11–22: CureVac AG Promising Cancer Vaccines in the Clinical Development
Table 11–23: DCprime Promising Cancer Vaccines in the Clinical Development
Table 11–24: Vaximm AG Promising Cancer Vaccines in the Clinical Development
Table 11–25: Anixa Biosciences, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–26: AdaptVac Promising Cancer Vaccines in the Clinical Development
Table 11–27: PDC*line Pharma Promising Cancer Vaccines in the Clinical Development
Table 11–28: MimiVax LLC Promising Cancer Vaccines in the Clinical Development
Table 11–29: Agenus, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–30: AlphaVax Promising Cancer Vaccines in the Clinical Development
Table 11–31: Genexine Promising Cancer Vaccines in the Clinical Development
Table 11–32: GlobeImmune, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–33: Ubivac Promising Cancer Vaccines in the Clinical Development
Table 11–34: Vaccinogen Promising Cancer Vaccines in the Clinical Development
Table 11–35: OSE Immunotherapeutics Promising Cancer Vaccines in the Clinical Development
"

  • Global BCG Vaccine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 96
    According to our LPI (LP Information) latest study, the global BCG Vaccine market size was valued at US$ 365.6 million in 2023. With growing demand in downstream market, the BCG Vaccine is forecast to a readjusted size of US$ 542.8 million by 2030 with a CAGR of 5.8% during review period. The research report highlights the growth potential of the global BCG Vaccine market. BCG Vaccine are expected to show stable growth in the future market. However, product differentiation, reducing cost......
  • Global Peptide Cancer Vaccine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 115
    According to our LPI (LP Information) latest study, the global Peptide Cancer Vaccine market size was valued at US$ 535 million in 2023. With growing demand in downstream market, the Peptide Cancer Vaccine is forecast to a readjusted size of US$ 1978.2 million by 2030 with a CAGR of 20.5% during review period. The research report highlights the growth potential of the global Peptide Cancer Vaccine market. Peptide Cancer Vaccine are expected to show stable growth in the future market. How......
  • Global Cancer Vaccine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 26-Dec-2023        Price: US 3380 Onwards        Pages: 101
    Market Overview of Global Cancer Vaccine market: According to our latest research, the global Cancer Vaccine market looks promising in the next 5 years. As of 2022, the global Cancer Vaccine market was estimated at USD 7198.2 million, and it's anticipated to reach USD 33936.62 million in 2028, with a CAGR of 29.49% during the forecast years. A cancer vaccine is a type of immunotherapy that boost the body's natural defenses by stimulating the immune system to recognize and cur......
  • Global Lung Cancer Vaccines Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 12-Dec-2023        Price: US 3380 Onwards        Pages: 102
    Market Overview of Global Lung Cancer Vaccines market: According to our latest research, the global Lung Cancer Vaccines market looks promising in the next 5 years. As of 2022, the global Lung Cancer Vaccines market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Lung Cancer Vaccines,A cancer vaccine for lung cance This report covers a research time span from 2018 to 2028, and ......
  • Global Cancer Vaccines Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 07-Dec-2023        Price: US 3380 Onwards        Pages: 105
    Market Overview of Global Cancer Vaccines market: According to our latest research, the global Cancer Vaccines market looks promising in the next 5 years. As of 2022, the global Cancer Vaccines market was estimated at USD 5773.14 million, and it's anticipated to reach USD 15406.41 million in 2028, with a CAGR of 17.77% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cancer Vacci......
  • Global Dendritic Cell Cancer Vaccine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 16-Nov-2023        Price: US 3380 Onwards        Pages: 110
    Market Overview of Global Dendritic Cell Cancer Vaccine market: According to our latest research, the global Dendritic Cell Cancer Vaccine market looks promising in the next 5 years. As of 2022, the global Dendritic Cell Cancer Vaccine market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Dendritic cells (DC) are one of the major antigen presenting cells found in lymphoid organs. The main fu......
  • Global BCG Vaccine Market Research Report 2023, Forecast to 2028
    Published: 14-Nov-2023        Price: US 2680 Onwards        Pages: 135
    BCG Vaccine is not given as part of the routine NHS vaccination schedule. It's given on the NHS only when a child or adult is thought to have an increased risk of coming into contact with TB. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage o......
  • Global BCG Vaccine Professional Survey Report 2023, Forecast to 2028
    Published: 14-Nov-2023        Price: US 3280 Onwards        Pages: 105
    BCG Vaccine is not given as part of the routine NHS vaccination schedule. It's given on the NHS only when a child or adult is thought to have an increased risk of coming into contact with TB. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage o......
  • Infectious Vaccine Collaboration and Licensing Deals 2016-2023
    Published: 01-Nov-2023        Price: US 3995 Onwards        Pages: 300
    Infectious Vaccine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the infectious vaccine deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of infectious vaccine deals from 2016 to 2023. The report provides a detailed understanding and analysis of how and why companies enter infectious vaccine deals. These deals tend to be multicomponent, starting with......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs